Medeze Group

Medeze Group Net Margin

The Net Profit Margin of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is 26.41 %. In the previous year, Net Profit Margin was 40.85 % — a change of -35.36% (lower).

Net Margin

26.41 %

YoY

-35.36%

Last updated:

Net Profit Margin of Medeze Group is 2025 26.41 % . Net Profit Margin of Medeze Group was 2024 40.85 % . It decreases by -35.36% lower compared to the previous year.

Medeze Group's net margin stands at 26.4%, broadly stable from 26.3% several years earlier.

The Medeze Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
75.86 THB
Jan 1, 2019
-63.80 THB
Jan 1, 2020
101.37 THB
Jan 1, 2021
26.29 THB
Jan 1, 2022
25.30 THB
Jan 1, 2023
34.14 THB
Jan 1, 2024
40.85 THB
Jan 1, 2025
26.41 THB
The Medeze Group Net Margin history
YEARNet MarginYoY
26.41 %-35.36%
40.85 %+19.67%
34.14 %+34.93%
25.30 %-3.77%
26.29 %-74.07%
101.37 %-258.89%
-63.80 %-184.10%
75.86 %-18.63%
93.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

Net Profit Margin of Medeze Group is 26.41 % in 2025.

Net Profit Margin of Medeze Group changed from 40.85 % to 26.41 %, representing a -35.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Medeze Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Medeze Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Medeze Group

All Key Metrics — Medeze Group